Mariposa Technologies Inc joins American Heart Association Innovators’ Network
Mariposa Technologies Inc, the designer of technology and tools to make life…
May 18, 2018
AHA and BMS/Pfizer: Identifying undiagnosed, asymptomatic AFib
It is estimated that more than 5 million people in the United State are diagnosed with NVAF and an additional 3 million have AFib and don’t know it (Colilla S et al. Am J Cardiol.2014;pii: S0002-9149(13)-1288). The BMS/Pfizer Alliance and AHA are working together to identify undiagnosed patients and provide digital tools to manage the condition. The first phase of this study involves the development of a screening tool using a combination of pharmacy, hospital, claims and EHR data in order to identify patients at high risk for having or developing AFib. AHA and its team of expert advisors are designing the tool with the intent of practical clinical implementation and scalability. Success of this tool has the potential to save millions of lives by reducing the risk of stroke in AFib patients who don’t even know they have AFib.
More News
-
-
Digital Technologies in Cardiac Rehabilitation: A Science Advisory From the American Heart Association
-
Quick Reminder: Submit Your Abstracts for Scientific Sessions 2023 by June 8th!
Time is running out to submit to have your Science at AHA…
-
Join Members of the AHA Innovators’ Network to Discuss Women’s Heart Health
In honor of National Women’s Health Month, the American Heart Association’s Center for…